Comparison of angiopoietin-like protein 3 and 4 reveals structural and mechanistic similarities

Autor: Jian Liu, Kathryn H. Gunn, Yongmei Xu, Aspen R. Gutgsell, Caitlin V. Johnson, Saskia B. Neher
Rok vydání: 2021
Předmět:
0301 basic medicine
Very low-density lipoprotein
SEC
size-exclusion chromatography

Protein Conformation
CAD
coronary artery disease

small-angle X-ray scattering (SAXS)
very-low-density lipoprotein (VLDL)
Coronary Artery Disease
Lipoproteins
VLDL

Biochemistry
Substrate Specificity
DGGR
1
2-Di-O-lauryl-rac-glycero-3-glutaric acid 6′-methylresorufin ester

03 medical and health sciences
Non-competitive inhibition
ANGPTL4
enzyme kinetics
protein purification
ANGPTL3
Protein purification
medicine
Angiopoietin-Like Protein 4
Humans
Enzyme kinetics
Molecular Biology
Triglycerides
lipoprotein lipase (LPL)
Angiopoietin-Like Protein 3
lipoprotein metabolism
Lipoprotein lipase
noncompetitive inhibition
030102 biochemistry & molecular biology
Heparin
Chemistry
SAXS
small-angle X-ray scattering

VLDL
very-low-density lipoprotein

Cell Biology
Lipoprotein Lipase
Angiopoietin-like Proteins
heparin-binding protein
LPL
lipoprotein lipase

NEFA
nonesterified fatty acid

030104 developmental biology
Protein Binding
Research Article
medicine.drug
Zdroj: The Journal of Biological Chemistry
ISSN: 0021-9258
DOI: 10.1016/j.jbc.2021.100312
Popis: Elevated plasma triglycerides are a risk factor for coronary artery disease, which is the leading cause of death worldwide. Lipoprotein lipase (LPL) reduces triglycerides in the blood by hydrolyzing them from triglyceride-rich lipoproteins to release free fatty acids. LPL activity is regulated in a nutritionally responsive manner by macromolecular inhibitors including angiopoietin-like proteins 3 and 4 (ANGPTL3 and ANGPTL4). However, the mechanism by which ANGPTL3 inhibits LPL is unclear, in part due to challenges in obtaining pure protein for study. We used a new purification protocol for the N-terminal domain of ANGPTL3, removing a DNA contaminant, and found DNA-free ANGPTL3 showed enhanced inhibition of LPL. Structural analysis showed that ANGPTL3 formed elongated, flexible trimers and hexamers that did not interconvert. ANGPTL4 formed only elongated flexible trimers. We compared the inhibition of ANGPTL3 and ANGPTL4 using human very-low-density lipoproteins as a substrate and found both were noncompetitive inhibitors. The inhibition constants for the trimeric ANGPTL3 (7.5 ± 0.7 nM) and ANGPTL4 (3.6 ± 1.0 nM) were only 2-fold different. Heparin has previously been reported to interfere with ANGPTL3 binding to LPL, so we questioned if the negatively charged heparin was acting in a similar fashion to the DNA contaminant. We found that ANGPTL3 inhibition is abolished by binding to low-molecular-weight heparin, whereas ANGPTL4 inhibition is not. Our data show new similarities and differences in how ANGPTL3 and ANGPTL4 regulate LPL and opens new avenues of investigating the effect of heparin on LPL inhibition by ANGPTL3.
Databáze: OpenAIRE